We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Study Indicates Bariatric Embolization is Safe for Morbidly Obese Individuals

By MedImaging International staff writers
Posted on 16 Feb 2017
Image: A left gastric artery angiography (black arrow) showing fundus of stomach (dashed arrows) (Photo courtesy of RSNA).
Image: A left gastric artery angiography (black arrow) showing fundus of stomach (dashed arrows) (Photo courtesy of RSNA).
Bariatric embolization, a novel interventional radiology technique that helps patients lose weight, has been found to be safe and well tolerated by morbidly obese individuals.

The new procedure reduces the production of the hormone ghrelin in the stomach, and was found to result in an average weight loss of 5.9% in one month, and 9.0% in three months.

The researchers from the Johns Hopkins University School of Medicine published the results of their study in the February 2017, online edition of the journal Radiology. The current phase of the study included the results of the treatment of four female and one male patient, all morbidly obese and with a mean Body Mass Index (BMI) of 43.8. The procedure consisted of embolization of the patients' left gastric artery with 300- to 500-micrometer beads, using fluoroscopic guidance.

The results showed that serum ghrelin hormone levels in the patients dropped on average by 17.5%, at three months, and also resulted in an improvement in quality-of-life parameters without major adverse events for the study group. The researchers noted that bariatric embolization is not intended as a first-line treatment for obesity, nor is it intended to replace bariatric surgery.

Lead author of the study, Clifford R. Weiss, MD at Johns Hopkins University School of Medicine, said, “A number of research papers in the 1990s found signs of hormonal changes after bariatric surgery. In particular, there was a pretty rapid reduction in ghrelin, the most potent hunger-stimulating hormone we know. The hormone is produced in an area of the stomach called the fundus, which is fed primarily by the left gastric artery. These are very promising and exciting results. I think this paper and the additional data we’re compiling show that bariatric embolization is very well tolerated by patients, and there are signs that it could have medium- and long-term efficacy for weight loss. Obesity is a complicated disease that takes many different therapies to treat, including psychological counseling, diet, medication and, in extreme cases, surgery. If we can provide one more piece to the armamentarium, that would be an exciting next step in the treatment of obese patients.”

X-ray Diagnostic System
FDX Visionary-A
New
Diagnostic Ultrasound System
DC-80A
Wall Fixtures
MRI SERIES
Digital X-Ray Detector Panel
Acuity G4

Channels

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.